Medicinal chemistry of target family-directed masterkeys

被引:184
作者
Müller, G [1 ]
机构
[1] Axxima Pharmaceut AG, D-81377 Munich, Germany
关键词
D O I
10.1016/S1359-6446(03)02781-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The majority of pharmaceutically relevant drug targets cluster into densely populated target families, thus offering a novel approach that complements the currently favoured screening paradigm in medicinal chemistry. This approach uses a privileged structure concept whereby molecular masterkeys are developed that account for a target family wide structural or functional commonality. Numerous lead compounds, based on multipurpose privileged structures, can be generated that address a variety of targets from a gene family of interest, irrespective of therapeutic area. Several different interpretations of the privileged structure concept will be highlighted, with a strong emphasis on the most stringent application: the optimization of a molecular masterkey for a distinct target family of interest.
引用
收藏
页码:681 / 691
页数:11
相关论文
共 43 条
  • [1] Safety and efficacy of low-energy cardioversion of 500 patients using two different techniques
    Andraghetti, A
    Scalese, M
    [J]. EUROPACE, 2001, 3 (01): : 4 - 9
  • [2] Pyrrolidine-5,5-trans-lactams.: 2.: The use of X-ray crystal structure data in the optimization of P3 and P4 substituents
    Andrews, DM
    Chaignot, H
    Coomber, BA
    Good, AC
    Hind, SL
    Johnson, MR
    Jones, PS
    Mills, G
    Robinson, JE
    Skarzynski, T
    Slater, MJ
    Somers, DO
    [J]. ORGANIC LETTERS, 2002, 4 (25) : 4479 - 4482
  • [3] [Anonymous], 2001, REVOLUTION R D GENOM
  • [4] The properties of known drugs .1. Molecular frameworks
    Bemis, GW
    Murcko, MA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) : 2887 - 2893
  • [5] Properties of known drugs. 2. Side chains
    Bemis, GW
    Murcko, MA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (25) : 5095 - 5099
  • [6] Trends in development cycles
    Bolten, BM
    DeGregorio, T
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (05) : 335 - 336
  • [7] Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease.: 1.: The α-methyl-trans-lactam template
    Borthwick, AD
    Angier, SJ
    Crame, AJ
    Exall, AM
    Haley, TM
    Hart, GJ
    Mason, AM
    Pennell, AMK
    Weingarten, GG
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (23) : 4452 - 4464
  • [8] Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease.: 2.: Potency and chirality
    Borthwick, AD
    Crame, AJ
    Ertl, PF
    Exall, AM
    Haley, TM
    Hart, GJ
    Mason, AM
    Pennell, AMK
    Singh, OMP
    Weingarten, GG
    Woolven, JM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (01) : 1 - 18
  • [9] TIFLUADOM, A KAPPA-OPIATE AGONIST, ACTS AS A PERIPHERAL CHOLECYSTOKININ RECEPTOR ANTAGONIST
    CHANG, RSL
    LOTTI, VJ
    CHEN, TB
    KEEGAN, ME
    [J]. NEUROSCIENCE LETTERS, 1986, 72 (02) : 211 - 214
  • [10] New goals for the US Human Genome Project: 1998-2003
    Collins, FS
    Patrinos, A
    Jordan, E
    Chakravarti, A
    Gesteland, R
    Walters, L
    Fearon, E
    Hartwelt, L
    Langley, CH
    Mathies, RA
    Olson, M
    Pawson, AJ
    Pollard, T
    Williamson, A
    Wold, B
    Buetow, K
    Branscomb, E
    Capecchi, M
    Church, G
    Garner, H
    Gibbs, RA
    Hawkins, T
    Hodgson, K
    Knotek, M
    Meisler, M
    Rubin, GM
    Smith, LM
    Smith, RF
    Westerfield, M
    Clayton, EW
    Fisher, NL
    Lerman, CE
    McInerney, JD
    Nebo, W
    Press, N
    Valle, D
    [J]. SCIENCE, 1998, 282 (5389) : 682 - 689